New U.S. investor The Institute for Follicular Lymphoma Innovation (IFLI), a global non-profit foundation dedicated to advancing research and treatment for follicular lymphoma, invested $9 million in ...

SpliceBio, a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused by mutations in large genes, today announced the close of a $135 million Series B financing ...

Instil Bio, Inc. ("Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of ...

Topline data were announced from two phase 3 trials evaluating enlicitide decanoate for the treatment of adults with hyperlipidemia.

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy ...

Merck's oral PCSK9 inhibitor enlicitide showed significant LDL-C reductions in two Phase 3 trials, with no major safety ...

Ibogaine is a plant-based psychedelic substance that's extracted from the roots of an iboga plant. It has been used in ...

Tiziana (TLSA) is showing groundbreaking advancements in Alzheimer's & MS treatments with foralumab. Key trials & market ...

Mayo Clinic is dedicated to driving progress and expanding its impact through innovation. This initiative is an exciting ...

Ultimately, Stoke Therapeutics is that classic “intriguing biotech” --hurdling to one of those proverbial “moments of truth” ...

On May 30, a team of researchers funded by the National Institutes of Health got the word: Funding for their vaccine ...